Glucose6phosphateisomerase抗体;Glucose6phosphateisomerase Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Glucose 6 phosphate isomerase expression in HeLa cell lysate.    

  
  

Glucose-6-phosphate isomerase (GPI), also known as phosphoglucose isomerase or neuroleukin, is a multifunctional enzyme involved in glycolysis and gluconeogenesis, catalyzing the reversible isomerization of glucose-6-phosphate and fructose-6-phosphate. Beyond its metabolic role, GPI exhibits cytokine-like activity, acting as a neurotrophic factor (neuroleukin) and an autocrine motility factor (AMF) that influences cell migration and differentiation.

Anti-GPI antibodies have garnered significant attention in autoimmune diseases, particularly rheumatoid arthritis (RA). Studies suggest that GPI autoantibodies contribute to joint inflammation by forming immune complexes that activate complement pathways and recruit inflammatory cells. In murine models, GPI immunization induces arthritis resembling human RA, highlighting its pathogenic potential. These antibodies are detected in a subset of RA patients and correlate with disease severity, making them potential biomarkers for diagnosis or prognosis.

Additionally, GPI antibodies are implicated in other conditions, including systemic lupus erythematosus (SLE) and certain cancers, where they may influence tumor progression or immune evasion. Research continues to explore their mechanistic roles and therapeutic targeting, such as blocking GPI-antibody interactions to mitigate inflammation. Understanding GPI antibodies bridges metabolic dysregulation, autoimmunity, and cancer biology, offering insights for novel diagnostic and therapeutic strategies.